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STUDIES on the neoplastic potential of
substituted hydrazines have been under
way in this laboratory since 1968. These
investigations are carried out in randomly
bred Swiss albino mice and Syrian
hamsters, and chemicals are administered
at the maximum tolerated dose con-
tinuously in drinking water for life. To
date, 24 hydrazines are known to produce
tumours in laboratory animals (Bianci-
fiori and Ribacchi, 1962; Clayson et al.,
1966; Druckrey et al., 1966, 1967; Kelley
et al., 1969; Toth, Nagel and Kupper,
1975; Toth, 1975). According to a recent
estimate (Toth, 1975) well over a hundred
hydrazine derivatives are in the environ-
ment and many of these coinpounds are
widely used in industry, agriculture and
medicine. It has recently been pointed
out that 5 chemicals of this class occur
naturally, in tobacco and in some edible
mushrooms. Two were previously shown
to induce tumours in animals, while
studies with the other 3 compounds are in
progress (Toth, 1975).
The present work records the tumouri-
genicity of allylhydrazine HCI given to
Swiss mice daily in drinking water for life.
Swiss albino mice from the colony
randomly bred by us since 1951 were used.
They were housed in plastic cages with
granular cellulose bedding, separated
according to sex in groups of ten, and
given Wayne Lab Blox diet in regular
pellets (Allied Mills, Inc., Chicago, Illinois)
and tap water or the test solution ad
libitum as described below.
The chemical used was allyhydrazine
HCI (ALH), CH2 CH-CH2-NH-NH21
HCl, mol. wt.: 108 56, m.p.: >250°C,
puirity: 9800 by gas chromatography,
synthesized in this laboratory. The
0.0125% solution which was used for the
chronic experiment was analysed by gas
chromatography after 48 h standing and
found to contain more than 9700 of the
original compound.
Allylhydrazine oxalate was synthes-
ized as follows: over a period of 1X5 h,
36 g of allylbromide was added to a
vigorously stirred solution of 150 g of
hydrazine hydrate maintained at 50°C.
After being stirred for 2 h the solution
was continuouslyextractedwithethylether
for 20 h. The ether was removed by distil-
lation and the residue poured into 35 g of
oxalic acid dissolved in one litre of 950o
ethanol. The resulting oxalate salt was re-
crystallized from ethanol, m.p. 160-161TC.
Analysis calculated for C5H1oN204:
C, 37 04; H, 6-17; N 17-28. Found: C,
37-18; H, 6 ]5; N, 17-11.
Preparation of the allylhydrazine HCI
stock solution: the above oxalate was
added to a cold solution containing an
equal weight of NaOH and 400 ml of
water. The solution was distilled to near
dryness (370 ml of distillate collected).
An aliquot of the distillate was titrated
with 0-1N HCI to a methyl red end-point
and the concentration of allylhydrazine
was calculated. The distillate was acidi-
fied with HCI to a pH of 4-5 and the
concentration adjusted to 500. The solu-
tion was stored in a dark bottle under
refrigeration.
A toxicity study was carried out prior
to the chronic experiment. Five doseALLYLHYDRAZINE HCL TUMOURIGENESIS
levels of ALH (viz., 0 1, 0 05, 0-025,
0.0125, and 0 00625%) were administered
in the drinking water daily for 35 days to
Swiss mice. Taking into account four
parameters, survival, body wt., consump-
tion of chemical and histological changes,
the 0.0125% was found to be suitable for
the lifelong treatment. This toxicity
technique was developed in this laboratory
and published recently (Toth, 1972).
The solutions were prepared thrice
weekly, and their total consumption by
the mice was measured at the same
intervals during the treatment period.
The solution was stored in brown bottles
because of the possible light sensitivity of
the chemical. The chronic experimental
groups and the controls were as follows:
Group 1.-ALH was dissolved in the
drinking water as a 0.0125% solution and
given for the life span of 50 female and 50
male mice which were 5 weeks (38 days)
old at the beginning of the experiment.
The average daily consumption of the
ALH solution per animal was 8 1 ml for
females and 10 4 ml for the males. The
average daily intake ofALH was therefore
1 0 mg for a female and 1-3 mg for a male.
Group 2.- As an untreated control, 100
female and 100 male mice were kept and
observed from weaning time (5 weeks of
age).
The experimental and control animals
were carefully checked and weighed at
weekly intervals and the gross pathologic
changes were recorded. The animals
were either allowed to die or were killed
with ether when found in poor condition.
Complete necropsies were performed on
all animals. All organs were examined
macroscopically and histological studies
were made on the liver, spleen, kidney,
bladder, thyroid, heart, pancreas, testis,
brain, nasal turbinale, and at least four
lobes of the lungs ofeach mouse as well as
on those organs showing gross pathological
changes. These tissues were fixed in 10%
buffered formalin and stained routinely
with haematoxylin and eosin.
The treatment significantly shortened
the survival time when compared with the
life span of the untreated controls. At
the 80th, 90th, and 100th weeks, 33, 18
and 8 females and 9, 5, and 0 males were
alive in the treated groups while in
controls the corresponding figures were
71, 57 and 36 females and 65, 48 and 27
males.
The number, percentages of animals
with tumours, and their age at death
TABLE.-Treatment and Tumour Distribution in Allylhydrazine HCI (ALH)-treated
Swiss Mice
Treatment
001250%
ALH iri
drinking
water
daily
for
life,
Effective
no.
and
sex
50Y
Lung tumours
No. % Latent period*
25 50 85 (40-100)
Animals with:
Blood vessel tumours
No. % Latent period*
9 18 83 (54-110)
49 d 23 46 74 (47-96) 1 2 61
* Average in weeks (and range).
t Latent period in parentheses.
Other tumourst
11 Malignant lymphomata
(41,54, 55, 76,80,84, 84,
95, 95, 110, 110)
2 Fibrosarcomata,
subcutaneous (76, 103)
1 Fibrosarcoma,
abdominal (97)
1 Granulosa cell tumour
(80)
1 Adenocarcinoma of
ovary (83)
1 Adenocarcinoma of
skin appendages (65)
6 Malignant lymphomata
(21, 62, 68, 68, 77, 82)
2 Hepatomata (58,94)
1 Malignant histiocytoma
(64)
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(latent periods) are summarized in the
Table. The two most important neo-
plasms are described in detail below.
Lung tumours.-Ofthe treated females,
25 (500o) developed 65 lung tumours.
Of these, 15 had 29 adenomata, 3 had 7
adenocarcinomata, and 7 had both adeno-
mata and adenocarcinomata (16+13
respectively). The average age at death
was 85 weeks. The first tumour was
found at the 40th week and the last at the
100th week of age. Of the treated males,
23 (46%) developed 49 lung tumours.
Out of these, 14 had 24 adenomata, 2 had
3 adenocarcinomata and 7 had both
adenomata and adenocarcinomata (7+9
respectively). The average age at death
was 74 weeks. The first tumour was
observed at the 47th week and the last at
the 96th week of age.
Macroscopically and histologically,
these neoplasms appeared similar to those
described previously in this mouse strain
in this laboratory (Toth, Magee and
Shubik, 1964; Toth and Shimizu, 1974).
Blood vessel tumours.-Of the treated
females, 9 (18%) developed such tumotrs.
Of these, 2 had angiosarcomata in the
liver, one had angiosarcoma in muscle, 3
had angiomata in the liver, 2 had angio-
mata in the ovary and one had an angioma
in a lymph node. The average age at
death was 83 weeks, the first tumour was
found at the 54th week and the last at the
110th week of age. In the treated males,
only one angioma of the heart was found,
at the 61st week of age.
Grossly and histologically, the blood
vessel tumours were similar to those found
earlier in the variously treated mice and
described in detail (Toth and Wilson,
1971; Toth, 1973).
Other tumours. As can be seen in the
Table, a few tumours of other types were
also observed in the treated animals. As
they were found in low incidences, they
cannot be attributed to the treatment.
Tumours in untreated controls. The
number and types of tumours occurring
spontaneously in the control mice were
described recently (Toth and Shimizu,
1974). Another untreated control group
running parallel with the allylhydrazine
HCl treated mice is nearly completed.
They exhibit similar types and incidences
of neoplasms to the previous groups of
untreated mice.
This study demonstrates for the first
time the tumourigenicity ofallylhydrazine
HCl administered daily in drinking water
for life to Swiss mice. The incidence of
lung tumours rose from 21 to 5000 in
females and from 23 to 46% in males,
while the incidence of blood vessel
tumours increased from 5 to 188% in the
females, but not in the males, when
compared with untreated controls.
Statistical analysis showed that the
increased incidence of tumours of the
lungs and blood vessels is significant at the
500 level of probability. (Food Protec-
tion Committee, Food and Nutrition
Board, 1960). Histopathologically, the
tumours of lungs were diagnosed as
adenomata and adenocarcinomata, while
the vascular lesions exhibited the charac-
teristic appearances of angiomata and
angiosarcomata.
Hydrazine derivatives have been
shown to inhibit spermatogenesis in a
manner similar to that of steroids, by
inhibition of pituitary gonadotrophin
function (Paget, Walpole and Richardson,
1961). Of the several substituted hydra-
zines which were synthesized for this
purpose, the most potent is 1-(Qx-methyl-
allylthiocarbamoyl) - 2 - (methylthiocarba-
moyl) hydrazine, which was under clinical
trial, which was discontinued because of
side-effects (Walpole, 1965). The allyl
group was shown to be crucial for activity
(Bennett, 1974).
This study is part of a programme
dealing with the interaction of chemical
structure and tumour development at
specific organ sites. By altering the
radical chain(s) attached to the hydrazine
moiety, it was our hope to gain futher
insight into the mode of action of hydra-
zines. The allyl group is known to be a,
very reactive species both in radical and
carbonium ion forms. Hence, if allyl-
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hydrazine produced such an intermediate,
substantial alteration in activity or speci-
ficity in the induction tumour types might
be expected. This hypothesis, however,
was not substantiated, since some of the
mono- and dialkyl-derivatives, including
the ethyl-, carbamyl-, 1,2-dimethyl-, and
1,1-dimethylhydrazines, induced identical
types of neoplasms to the allyl derivative
(Shimizu, Nagel and Toth, 1974; Toth,
1973; Toth et al., 1975; Toth and Wilson,
1971; Toth Shimizu and Erickson, 1975).
The authors are grateful to Mr James
Erickson and Mr Kenneth Phelps for their
technical assistance in the experiment.
This investigation was supported by
Public Health Service Contract PH43-
NCI-E-68-959 from the National Cancer
Institute, NIH, USA.
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